Q2 2019 13F Holders as of 6/30/2019
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
55.7M
-
Number of holders
-
59
-
Total 13F shares, excl. options
-
10.6M
-
Shares change
-
+1.38M
-
Total reported value, excl. options
-
$122M
-
Value change
-
+$15.8M
-
Number of buys
-
33
-
Number of sells
-
-12
-
Price
-
$11.51
Significant Holders of Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) as of Q2 2019
62 filings reported holding SPRO - Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2019.
Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) has 59 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 10.6M shares
of 55.7M outstanding shares and own 19.1% of the company stock.
Largest 10 shareholders include Atlas Venture Associates IX, LLC (1.38M shares), Aquilo Capital Management, LLC (1.15M shares), Alphabet Inc. (1.11M shares), BVF INC/IL (940K shares), BlackRock Inc. (657K shares), AWM Investment Company, Inc. (598K shares), Artal Group S.A. (540K shares), Rock Springs Capital Management LP (525K shares), ORBIMED ADVISORS LLC (507K shares), and VHCP Management II, LLC (474K shares).
This table shows the top 59 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.